Side-by-side · Research reference
AdipotidevsCagrilintide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED15/49 cited
BPhase 3HUMAN-REVIEWED35/64 cited
Adipotide
Pro-apoptotic Vascular-Targeting Peptide · Preclinical Only
IV · Systemic · Preclinical Protocols OnlyHossen 2013
01Mechanism of Action
Parameter
Adipotide
Cagrilintide
Primary target
Prohibitin-1 (PHB1) on adipose vasculature endotheliumHossen 2013
Amylin receptor (AMYR) and calcitonin receptor (CTR) heterodimeric complexesBailey 2026
Pathway
CKGGRAKDC domain binds PHB1 → Peptide internalisation → D(KLAKLAK)₂ mitochondrial membrane disruption
AMYR/CTR agonism → Central satiety signaling → Reduced food intake, delayed gastric emptying, suppressed glucagonBailey 2026
Downstream effect
Endothelial apoptosis → Adipose vascular collapse → Adipocyte involution → Weight loss
Central satiety induction, prandial glucagon suppression, reduced caloric intake, weight loss, improved glycemic controlBailey 2026Yamauchi 2026
Feedback intact?
N/A — Direct apoptotic mechanism, non-hormonal
Yes — acts via physiological amylin pathways
Origin
Synthetic bioconjugate: PHB1-targeting homing peptide + pro-apoptotic KLA sequence
Second-generation non-aggregating long-acting amylin analogue designed for once-weekly dosingBailey 2026
Antibody development
—
—
02Dosage Protocols
Parameter
Adipotide
Cagrilintide
Animal dose (mouse)
Low dose (not specified in abstract)Hossen 2013
Systemic injection in diet-induced obesity (DIO) models.Hossen 2013
—
Frequency
Not specified in available data
Once weekly (subcutaneous)Bailey 2026
Long-acting formulation.
Evidence basis
Preclinical animal models only
Phase 3 RCT (REDEFINE 5), meta-analysis of 3 RCTs (n=3545)Yamauchi 2026Ahmed 2026
Human data
None — no clinical trials reported
—
Standard dose (combination)
—
Cagrilintide 2.4 mg + Semaglutide 2.4 mg (CagriSema)Yamauchi 2026
Phase 3 REDEFINE 5 trial dosing.
Monotherapy dosing
—
Dose-dependent, under investigation
Monotherapy trials reported in meta-analysis.
03Metabolic / Fat Loss Evidence
Parameter
Adipotide
Cagrilintide
Primary fat target
White adipose tissue (all depots)
—
Mechanism
Vascular apoptosis → adipose blood supply collapse → adipocyte deathHossen 2013
Central satiety inductionBailey 2026
Body weight reduction
Significant reduction in DIO miceHossen 2013
Absolute values not provided in abstract.
—
Leptin levels
Significant decrease
Parallel to adipose mass reduction.
—
Effect on adipocytes
Antiobesity effect on dysfunctional adipose cells (adipocytes + macrophages)Hossen 2013
—
Ectopic fat
Reduction in ectopic fat depositionHossen 2013
Marker of dysfunctional adipose tissue / metabolic syndrome.
—
Species tested
Obese rhesus monkeys, DIO mice
—
Human translation
Unknown — no clinical trials
—
Weight loss vs semaglutide
—
7.47% greater percentage weight lossAhmed 2026
CagriSema combination vs semaglutide monotherapy (meta-analysis).
Absolute weight change
—
Significantly greater absolute weight reductionAhmed 2026
Mean difference favoring combination therapy.
Glycemic benefit
—
Reduced fasting glucose and HbA1cAhmed 2026
Synergistic effect with semaglutide in combination.
Body composition
—
Predominant fat loss with weight reduction
Mitochondrial function
—
In vitro effects on skeletal muscle mitochondria under metabolic stress conditionsOld 2026
C2C12 myotube study; clinical relevance under investigation.
Key publications
—
REDEFINE 5 (Yamauchi 2026) · Ahmed meta-analysis 2026 · Bailey review 2026Yamauchi 2026Ahmed 2026Bailey 2026
04Side Effects & Safety
Parameter
Adipotide
Cagrilintide
Safety profile
Unknown — preclinical data only
Generally consistent with incretin-based therapies
Phase 3 and meta-analysis safety data.
Vascular selectivity
Targets adipose vasculature; off-target vascular effects unknown
—
Apoptotic mechanism risk
Pro-apoptotic payload may affect unintended tissues if selectivity incomplete
—
Kidney / liver toxicity
Not reported in available data
—
Immunogenicity
Not assessed in available data
—
Gastrointestinal
—
Nausea, diarrhea (common with incretin-based therapies)Pardali 2026
Dietary management and nutritional monitoring recommended.
Injection site reactions
—
Local reactions possible with subcutaneous administration
Tolerability
—
Tolerability considerations similar to GLP-1RAs
Muscle preservation
—
Lean mass considerations during weight loss
In vitro mitochondrial effects observed; clinical impact under investigation.
Absolute Contraindications
Adipotide
- ·Human use — not approved, no clinical safety data
Cagrilintide
- ·Hypersensitivity to cagrilintide or formulation components
Relative Contraindications
Adipotide
- ·Any condition requiring intact adipose-tissue vascularisation
Cagrilintide
- ·Severe gastrointestinal disease
- ·History of pancreatitis (incretin-based therapy consideration)
05Administration Protocol
Parameter
Adipotide
Cagrilintide
1. Route
Intravenous injection (systemic) in preclinical models. No human protocols exist.
Once-weekly subcutaneous injection. Long-acting formulation designed for weekly administration schedule.Bailey 2026
2. Formulation
Bioconjugate peptide. May also be encapsulated in nanoparticles (prohibitin-targeted nanoparticle formulation, KLA-PTNP, showed superior efficacy vs. free bioconjugate in mice).Hossen 2013
Co-formulated with semaglutide as CagriSema for single weekly injection combining amylin and GLP-1 receptor agonism.Yamauchi 2026Bailey 2026
3. Preclinical dosing
Low-dose systemic injection (exact dosing not specified in available abstract). Frequency and duration not detailed.Hossen 2013
Subcutaneous — typically abdomen, thigh, or upper arm. Rotate injection sites weekly to minimize local reactions.
4. Storage
Not specified — likely requires peptide-grade lyophilised storage and reconstitution.
Refrigerate 2–8°C. Follow product-specific storage instructions for pre-filled pens or vials. Protect from light.
5. Dietary considerations
—
Nutritional monitoring recommended during treatment. Dietary management strategies important for tolerability and outcomes.Pardali 2026
06Stack Synergy
Adipotide
— no documented stacks
Cagrilintide
+ Semaglutide
StrongCagrilintide (amylin receptor agonist) and semaglutide (GLP-1 receptor agonist) act on distinct receptor systems to produce synergistic weight loss through complementary mechanisms — central satiety via amylin pathways plus incretin-mediated glucose control and appetite suppression via GLP-1. Co-formulated as CagriSema, this combination demonstrates 7.5% greater weight loss versus semaglutide monotherapy in Phase 3 trials with additional benefits on glycemic control and lipid parameters.
- CagriSema
- Cagrilintide 2.4 mg + Semaglutide 2.4 mg
- Frequency
- Once weekly subcutaneous
- Duration
- 26–52 weeks (trial data)
- Primary benefit
- Enhanced weight loss, improved glycemic control, multi-pathway metabolic modulation